Suppr超能文献

血管性血友病因子的裂解需要金属蛋白酶ADAMTS13的间隔域。

Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13.

作者信息

Zheng Xinglong, Nishio Kenji, Majerus Elaine M, Sadler J Evan

机构信息

Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri 63110, USA.

出版信息

J Biol Chem. 2003 Aug 8;278(32):30136-41. doi: 10.1074/jbc.M305331200. Epub 2003 Jun 5.

Abstract

ADAMTS13 consists of a reprolysin-type metalloprotease domain followed by a disintegrin domain, a thrombospondin type 1 motif (TSP1), Cys-rich and spacer domains, seven more TSP1 motifs, and two CUB domains. ADAMTS13 limits platelet accumulation in microvascular thrombi by cleaving the Tyr1605-Met1606 bond in von Willebrand factor, and ADAMTS13 deficiency causes a lethal syndrome, thrombotic thrombocytopenic purpura. ADAMTS13 domains required for substrate recognition were localized by the characterization of recombinant deletion mutants. Constructs with C-terminal His6 and V5 epitopes were expressed by transient transfection of COS-7 cells or in a baculovirus system. No association with extracellular matrix or cell surface was detected for any ADAMTS13 variant by immunofluorescence microscopy or chemical modification. Both plasma and recombinant full-length ADAMTS13 cleaved von Willebrand factor subunits into two fragments of 176 kDa and 140 kDa. Recombinant ADAMTS13 was divalent metal ion-dependent and was inhibited by IgG from a patient with idiopathic thrombotic thrombocytopenic purpura. ADAMTS13 that was truncated after the metalloprotease domain, the disintegrin domain, the first TSP1 repeat, or the Cys-rich domain was not able to cleave von Willebrand factor, whereas addition of the spacer region restored protease activity. Therefore, the spacer region is necessary for normal ADAMTS13 activity toward von Willebrand factor, and the more C-terminal TSP1 and CUB domains are dispensable in vitro.

摘要

ADAMTS13由一个解聚素和金属蛋白酶结构域(reprolysin-type metalloprotease domain)、一个解聚素结构域(disintegrin domain)、一个血小板反应蛋白1型基序(thrombospondin type 1 motif,TSP1)、富含半胱氨酸和间隔结构域、另外七个TSP1基序以及两个CUB结构域组成。ADAMTS13通过切割血管性血友病因子(von Willebrand factor)中的Tyr1605-Met1606键来限制微血管血栓中血小板的聚集,而ADAMTS13缺乏会导致一种致命综合征——血栓性血小板减少性紫癜(thrombotic thrombocytopenic purpura)。通过对重组缺失突变体的表征确定了底物识别所需的ADAMTS13结构域。带有C末端His6和V5表位的构建体通过COS-7细胞的瞬时转染或在杆状病毒系统中表达。通过免疫荧光显微镜或化学修饰,未检测到任何ADAMTS13变体与细胞外基质或细胞表面有联系。血浆和重组全长ADAMTS13均可将血管性血友病因子亚基切割成176 kDa和140 kDa的两个片段。重组ADAMTS13依赖二价金属离子,并被一名特发性血栓性血小板减少性紫癜患者的IgG抑制。在金属蛋白酶结构域、解聚素结构域、第一个TSP1重复序列或富含半胱氨酸结构域之后被截断的ADAMTS13无法切割血管性血友病因子,而添加间隔区可恢复蛋白酶活性。因此,间隔区对于ADAMTS13对血管性血友病因子的正常活性是必需的,而更靠C末端的TSP1和CUB结构域在体外是可有可无的。

相似文献

1
Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13.
J Biol Chem. 2003 Aug 8;278(32):30136-41. doi: 10.1074/jbc.M305331200. Epub 2003 Jun 5.
3
4
Binding of ADAMTS13 to von Willebrand factor.
J Biol Chem. 2005 Jun 10;280(23):21773-8. doi: 10.1074/jbc.M502529200. Epub 2005 Apr 11.
5
ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage.
Blood. 2003 Nov 1;102(9):3232-7. doi: 10.1182/blood-2003-03-0908. Epub 2003 Jul 17.
6
Interplay between ADAMTS13 and von Willebrand factor in inherited and acquired thrombotic microangiopathies.
Semin Hematol. 2005 Jan;42(1):56-62. doi: 10.1053/j.seminhematol.2004.09.008.
7
Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura.
Blood. 2004 Jun 15;103(12):4514-9. doi: 10.1182/blood-2003-12-4165. Epub 2004 Feb 19.
8
Thrombospondin-1 and ADAMTS13 competitively bind to VWF A2 and A3 domains in vitro.
Thromb Res. 2010 Oct;126(4):e260-5. doi: 10.1016/j.thromres.2010.07.009. Epub 2010 Aug 11.
9
Essential domains of a disintegrin and metalloprotease with thrombospondin type 1 repeats-13 metalloprotease required for modulation of arterial thrombosis.
Arterioscler Thromb Vasc Biol. 2011 Oct;31(10):2261-9. doi: 10.1161/ATVBAHA.111.229609. Epub 2011 Jul 28.
10
[ADAMTS13-Mediated Proteolytic Cleavage of Unusually Large von Willebrand Factor Polymers on Endothelial Cells in the Absence of Fluid Shear Stress].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Apr;32(2):532-540. doi: 10.19746/j.cnki.issn.1009-2137.2024.02.032.

引用本文的文献

1
Open or closed? Understanding the molecular mechanisms and clinical implications of ADAMTS13's conformation.
Hemasphere. 2025 Jul 27;9(7):e70189. doi: 10.1002/hem3.70189. eCollection 2025 Jul.
2
Thrombotic Thrombocytopenic Purpura in Pediatric Patients.
Biomedicines. 2025 Apr 25;13(5):1038. doi: 10.3390/biomedicines13051038.
3
Novel mechanisms of action of emerging therapies of hereditary thrombotic thrombocytopenic purpura.
Expert Rev Hematol. 2024 Jul;17(7):341-351. doi: 10.1080/17474086.2024.2356763. Epub 2024 May 20.
4
Mechanism underlying severe deficiency of plasma ADAMTS-13 activity in immune thrombotic thrombocytopenic purpura.
J Thromb Haemost. 2024 May;22(5):1358-1365. doi: 10.1016/j.jtha.2024.02.003. Epub 2024 Feb 14.
5
A novel mechanism underlying allosteric regulation of ADAMTS-13 revealed by hydrogen-deuterium exchange plus mass spectrometry.
Res Pract Thromb Haemost. 2022 Dec 13;7(1):100012. doi: 10.1016/j.rpth.2022.100012. eCollection 2023 Jan.
6
ADAMTS13 Biomarkers in Management of Immune Thrombotic Thrombocytopenic Purpura.
Arch Pathol Lab Med. 2023 Aug 1;147(8):974-979. doi: 10.5858/arpa.2022-0050-RA.
7
Mechanisms of ADAMTS13 regulation.
J Thromb Haemost. 2022 Dec;20(12):2722-2732. doi: 10.1111/jth.15873. Epub 2022 Sep 22.
8
ADAMTS13 conformations and mechanism of inhibition in immune thrombotic thrombocytopenic purpura.
J Thromb Haemost. 2022 Oct;20(10):2197-2203. doi: 10.1111/jth.15822. Epub 2022 Aug 3.
10
Insights Into Immunothrombosis: The Interplay Among Neutrophil Extracellular Trap, von Willebrand Factor, and ADAMTS13.
Front Immunol. 2020 Dec 2;11:610696. doi: 10.3389/fimmu.2020.610696. eCollection 2020.

本文引用的文献

1
ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165.
J Biol Chem. 2003 Jun 27;278(26):23656-65. doi: 10.1074/jbc.M212964200. Epub 2003 Apr 25.
3
Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab.
Ann Intern Med. 2003 Jan 21;138(2):105-8. doi: 10.7326/0003-4819-138-2-200301210-00011.
4
von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP.
Blood. 2003 Mar 1;101(5):1845-50. doi: 10.1182/blood-2002-08-2399. Epub 2002 Oct 17.
5
Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13).
Blood. 2002 Nov 15;100(10):3626-32. doi: 10.1182/blood-2002-05-1397. Epub 2002 Jul 12.
6
Autocatalytic cleavage of ADAMTS-4 (Aggrecanase-1) reveals multiple glycosaminoglycan-binding sites.
J Biol Chem. 2002 Nov 8;277(45):42775-80. doi: 10.1074/jbc.M205309200. Epub 2002 Aug 28.
7
A new name in thrombosis, ADAMTS13.
Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11552-4. doi: 10.1073/pnas.192448999. Epub 2002 Aug 23.
8
Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity.
Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11902-7. doi: 10.1073/pnas.172277399. Epub 2002 Aug 14.
9
Mucin-like domain of enteropeptidase directs apical targeting in Madin-Darby canine kidney cells.
J Biol Chem. 2002 Mar 1;277(9):6858-63. doi: 10.1074/jbc.m109857200.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验